Peer-reviewed research
An overview of the published evidence that informs Oprimaze's two-phase design. Every cited study links to its PubMed record — and we draw a clear line between what's well established, where research is still maturing, and which data is our own.
Appetite regulation
Hunger-driving hormones rise after weight loss and remain elevated for at least a year — pulling the body back toward its previous weight. Research on maintenance suggests structured, ongoing support improves the odds of keeping weight off.
Metabolic stability
Resting metabolic rate drops after sustained weight loss and stays suppressed, meaning the same intake yields weight gain. Published maintenance studies report better outcomes with structured protocols than with diet alone.
Post-injectable transition
Roughly two-thirds of weight lost on injectable therapy returns within 12 months of stopping in controlled trial settings — most of it in the first six months. A structured maintenance phase is the missing piece in most weight programs.
The appetite active
Oprimaze's active is a hemp-derived blend of THCV, CBD and CBC. THCV is non-intoxicating and interacts with CB1 receptors differently than THC — early research has studied it for appetite regulation. Preclinical studies have explored its role in food intake and energy expenditure; a small human trial reported encouraging metabolic findings — early evidence, not proof. We're honest about the maturity here: human appetite data is still emerging, and we ran our own 100-person consumer study on the formula rather than resting on the literature alone. It is a support tool, not a weight-loss drug.
Compliance & safety
The active is THCV — a distinct hemp-derived cannabinoid, not THC — so the blend contains no THC. Hemp is federally legal under the 2018 Farm Bill at up to 0.3% delta-9 THC; Oprimaze contains none, so it's fully compliant. It's non-intoxicating: it will not get you high. Every batch is third-party lab tested, and because there's no THC the formula is made to be non-detectable on standard workplace drug screens. A certificate of analysis is available per batch on request.
Nasal delivery
These cannabinoids are oil-loving and barely dissolve in water, so swallowed, most of a dose is lost to first-pass metabolism — oral bioavailability runs only ~6–19%. Oprimaze carries each active in a protein-stabilized liposome and delivers it nasally, straight past the liver: published pharmacokinetics put intranasal bioavailability for hemp-derived cannabinoids far higher, roughly 34–46%, which is why a low, gentle dose absorbs efficiently. (The 34–46% figure is delivery-science context from cannabidiol research, not an Oprimaze-specific measurement.)
Every published study we cite links to its PubMed record — and our own consumer study is always labeled as ours.